title: Construction and characterization of a new chimeric antibody against HER2.
abstract: OBJECTIVE
  Immunotherapy with anti-HER2 antibodies has shown promising results in patients with HER2-positive breast cancer. We have recently reported characterization of a mouse monoclonal antibody (mAb) against HER2, which binds to an epitope different from that recognized by trastuzumab and specifically inhibits proliferation of tumor cells overexpressing HER2. In the present study we report chimerization of this antibody.
  
  
  METHODS
  The immunoglobulin variable region heavy and light chain genes of 1T0 hybridoma cells were amplified and ligated to human γ-1 and κ constant region genes using splice overlap extension PCR. The chimeric antibody was subsequently expressed and characterized by ELISA, western blot and flow cytometry.
  
  
  RESULTS
  The purified chimeric antibody specifically binds to recombinant HER2 and HER2-overexpressing tumor cells and inhibits proliferation of these cells. The binding affinity of the chimeric mAb was comparable with the parental mouse mAb.
  
  
  CONCLUSIONS
  This chimeric anti-HER2 mAb is a potentially valuable tool for targeted immunotherapy.
authors.affiliation: Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad Mehdi
authors.initials: MM
authors.lastname: Amiri
authors.forename: Mahmood
authors.initials: M
authors.lastname: Jeddi-Tehrani
authors.forename: Tohid
authors.initials: T
authors.lastname: Kazemi
authors.forename: Motahareh
authors.initials: M
authors.lastname: Bahadori
authors.forename: Motahhare
authors.initials: M
authors.lastname: Bahadori
authors.forename: Mahshid
authors.initials: M
authors.lastname: Maddah
authors.forename: Mohammad
authors.initials: M
authors.lastname: Hojjat-Farsangi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Hojjat-Farsanghi
authors.forename: Jalal
authors.initials: J
authors.lastname: Khoshnoodi
authors.forename: Hodjatallah
authors.initials: H
authors.lastname: Rabbani
authors.forename: Fazel
authors.initials: F
authors.lastname: Shokri
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D006825:Hybridomas; D007116:Immunization, Passive / Q000379:methods*; D016056:Immunodominant Epitopes / Q000276:immunology; D051379:Mice; D058990:Molecular Targeted Therapy; D015202:Protein Engineering / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D016056:Immunodominant Epitopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins